Eidos Therapeutics Inc

Eidos Therapeutics — Merger or Acquisition (December 2020)

29 slides from Eidos Therapeutics's merger presentation, Dec 29, 2020

  1. Slide 1: December 2020 ISS Presentation

    December 2020 ISS Presentation Filed by Eidos Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Eidos Therapeutics, Inc. Commission File No.: 001-38533 The following presentatio

  2. Slide 2: Disclaimer

    Disclaimer This presentation is being made in respect of the proposed transaction involving Eidos and BridgeBio. BridgeBio filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission (“SEC”) that included a definitive joint proxy statement of BridgeBio and Eidos and a

  3. Slide 3: Disclaimer

    Disclaimer This presentation contains forward-looking statements relating to the proposed transaction involving Eidos and BridgeBio, including statements as to the expected timing, completion and effects of the proposed transaction. Statements in this presentation that are not statements of historic

  4. Slide 4: Why Now and Why the BridgeBio Transaction is the Best Option for Eidos Minority Stockholders

    Why Now and Why the BridgeBio Transaction is the Best Option for Eidos Minority Stockholders The BridgeBio Transaction Is More Compelling Than the Standalone Alternative Transaction leverages the broader capabilities and access to capital of BridgeBio Eidos is entering a critical phase of clinical d

  5. Slide 5: Section I: BridgeBio Transaction Is the Best Value Creation Opportunity

    Section I BridgeBio Transaction Is the Best Value Creation Opportunity Available to Minority Stockholders

  6. Slide 6: Compelling Premium to Unaffected Stock Price With Upside of Continued Ownership

    Compelling Premium to Unaffected Stock Price With Upside of Continued Ownership Based on today’s market values and 1.85x exchange ratio, Eidos minority stockholders will receive $128.54 per share in BridgeBio stock – significantly higher than at the time of the transaction announcement Implied value

  7. Slide 7: BridgeBio Merger Values Eidos at ~$5bn, 148% Premium to Unaffected Stock Price

    BridgeBio Merger Values Eidos at ~$5bn, 148% Premium to Unaffected Stock Price Merger Agreement Summary Trading History Since 10/05/20 Eidos Share Price BridgeBio Offer (1.85x BridgeBio Share Price) $128.54 $73.26 $51.92 Eidos Volume 12/08/20: Eidos and BridgeBio Record Date Price ($) Volume (mm) $1

  8. Slide 8: Special Committee Engagement Resulted in Significant Premium Transaction

    Special Committee Engagement Resulted in Significant Premium Transaction $69.48 +152% Share Price Performance Since June 2019 $127.50 +451% Eidos / Acoramidis Corporate 09/09/19: Announced Acoramidis Japan partnership with Alexion 11/16/19: Reported positive Acoramidis P2 15 month OLE data in ATTR-C

  9. Slide 9: Section II: BridgeBio Transaction Is More Compelling Than the Standalone Alternative

    Section II BridgeBio Transaction Is More Compelling Than the Standalone Alternative

  10. Slide 10: Proposed Merger with BridgeBio Delivers More Certainty of Value Than the Standalone Alternative

    Proposed Merger with BridgeBio Delivers More Certainty of Value Than the Standalone Alternative The Special Committee, after evaluating Eidos’ potential future financial performance with its advisors, determined that the negotiated terms were more compelling for minority stockholders than the standa

  11. Slide 11: Section III: Independent Special Committee Conducted Robust Process

    Section III Independent Special Committee Conducted Robust Process to Secure Highest Value Available for Minority Stockholders

  12. Slide 12: 2019 Discussions with BridgeBio – Special Committee Did Not Recommend Transaction

    2019 Discussions with BridgeBio – Determination by 2019 Special Committee to Not Recommend Transaction with BridgeBio Majority Stockholder Makes an Initial Acquisition Proposal: BridgeBio, which retained 63.2% ownership following Eidos’ IPO in 2017, offers to acquire all other outstanding shares of

  13. Slide 13: 2020 Discussions with BridgeBio – Agreement at Significantly Improved Value and Terms

    2020 Discussions with BridgeBio – 2020 Special Committee Reaches Agreement with BridgeBio at Significantly Improved Value and Terms to Eidos Minority Stockholders BridgeBio Makes Second Acquisition Proposal: In August 2020, Neil Kumar, on behalf of BridgeBio, informed the Eidos board that while no d

  14. Slide 14: Indication of Interest from Third-Party

    Indication of Interest from Third-Party Indication of Interest From Large International Pharmaceuticals Company: Subsequent to Eidos entering into a definitive agreement with BridgeBio, the Special Committee received a non-binding indication of interest from a third party for an acquisition of eithe

  15. Slide 15: Special Committee Attempted to Leverage Third Party Proposal to Maximize Value

    1 Determined that third party proposal could reasonably be expected to result in a superior proposal, and formally notified BridgeBio of that determination 2 Engaged in direct dialogue with the third party and secured an indication that it would be willing to pay more than $120 per share in cash for

  16. Slide 16: Section IV: BridgeBio Transaction Is the Only Actionable Alternative

    Section IV BridgeBio Transaction Is the Only Actionable Alternative for Minority Stockholders

  17. Slide 17: The Third Party Has Not Been Willing to Table an Actionable Offer

    The Third Party Has Not Been Willing to Table an Actionable Offer While the third-party has indicated its interest to Eidos, it has not made an actionable offer. There is no proposal on which the Special Committee could make a recommendation The proposals that the third party has put forward, includ

  18. Slide 18: Section V: Conclusion

    Section V Conclusion

  19. Slide 19: Conclusion: BridgeBio Transaction is Financially Compelling

    BridgeBio Transaction is Financially Compelling, Currently Valued at $128.54 Per Eidos Share or a 148% Premium to Eidos’ Unaffected Stock Price BridgeBio Merger Consideration Currently Offers Superior Value to the Third Party’s Indication of Interest as Well as to Eidos’ Standalone Value Special Com

  20. Slide 20: Section VI: Appendix

    Section VI Appendix

  21. Slide 21: Special Committee Director Biography

    William Lis has more than 28 years of biopharmaceutical experience. He also currently serves as executive chairman and interim chief executive officer of Jasper Therapeutics, Inc., which he led through a 2019 Series A financing. He served as chief executive officer and a director of Portola Pharmace

  22. Slide 22: Eidos at a glance

    7 Eidos at a glance i) Addressing large and growing unmet need in transthyretin (TTR) amyloidosis (ATTR), a fatal disease with limited treatment options Targeting the disease at its source by stabilizing TTR; validated mechanism designed to mimic naturally occurring rescue mutation Advancing acorami

  23. Slide 23: Company is led by proven team with expertise in genetic and cardiovascular medicine

    Company is led by proven team with expertise in genetic elf and cardiovascular medicine Led by industry veterans with over 30 INDs and more than 10 approved drugs Neil Kumar, PhD, CEO & Myokardia Prmoroce —_ McKinsey&Company Jonathan Fox, MD, PhD, President &CMO “J Myokardia ——_aguazeneca Smercx Uma

  24. Slide 24: ATTR is a systemic disease with multiple manifestations

    disease with multiple manifestations Transthyretin (TTR) amyloidosis (ATTR) is a systemic 7 &. ATTR wild-type cardiomyopathy (ATTRwt-CM) = Deposition of wild-type TTR amyloid in the heart, leading to predominantly diastolic heart failure Likely affects 400K+ worldwide, majority undiagnosed Late onse

  25. Slide 25: Opportunity in ATTR-CM growing as patients identified in broader cardiology populations

    Opportunity in ATTR-CM growing as patients identified in “7 broader cardiology populations lass compound in a large, gene ase market 13-19% 16% of heart failure with preserved of TAVR with “low gradient” ejection fraction!2 42 aortic stenosis* 8% ATTR-CM 3.4% of idiopathic bilateral carpal Likely >4

  26. Slide 26: ATTRibute-CM Phase 3 study expected to provide top-line data

    ATTRibute-CM Phase 3 study is expected to provide 7 top-line data in late 2021 or early 2022 l&) ANTICIPATED Update Expected timing ATTRibute-PN Phase 3 initiation 2H 2020 ATTRibute-CM Part A top-line data Late 2021 / Early 2022 ATTRibute-CM Part B top-line data 2023 We believe the company is well c

  27. Slide 27: Final Launch Preparation Tactics and Execution

    Final Launch Preparation Tactics and Execution Launch Readiness Brand Strategy Insights & Strategic Plan Market Development Critical Launch Readiness Activities *Core activities for new product launch (i.e., non-SNDA or generics) are compiled from 50+ product launches **Investment needs for cardiova

  28. Slide 28: Launch Standards for First-to-Launch Pharma Companies

    Launch Standards for First-to-Launch Pharma Companies Reference: Research Reveals New Launch Standards for First-to-Launch Pharma and Biotech Companies in the U.S., PharmExec, June 26, 2020 SG&A Spend vs. Forecasted Sales 2 Years Later SG&A Spend vs. Actual Sales 2 Years Later SG&A Investment = Sale

  29. Slide 29: BridgeBio and Eidos Exchange Ratio Since BridgeBio 2019 IPO

    BridgeBio and Eidos Exchange Ratio Since BridgeBio 2019 IPO Source: Public filings and FactSet as of 12/28/20. Note: Calculated as Eidos closing share price divided by BridgeBio closing share price on each date. (1) Calculated as Eidos VWAP divided by BridgeBio VWAP. (2) Calculated as average daily

Eidos Therapeutics — Merger or Acquisition (December 2020) on 6ix